Abstract:Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and increase survival rates. Aims To define the most efficient and cost‐effective method of early detection in clinical practice. Materials and Methods We collected the Information used to write this review by searching papers through PUBMED that were published from 2021 to 2024, mainly systematic reviews, meta‐analyses and clinical‐trials. We also included other older but notable papers that we found essential and valuable for understanding. Results EB‐OCT has a varied sensitivity and specificity—an average of 94.3% and 89.9 for each. On the other hand, detecting biomarkers via liquid biopsy carries an average sensitivity of 91.4% for RNA molecules detection, and 97% for combined methylated DNA panels. Moreover, CTCs detection did not prove to have a significant role as a screening method due to the rarity of CTCs in the bloodstream thus the need for more blood samples and for enrichment techniques. Discussion Although low‐dose CT scan (LDCT) is the current golden standard screening procedure, it is accompanied by a highly false positive rate. In comparison to other radiological screening methods, Endobronchial optical coherence tomography (EB‐OCT) has shown a noticeable advantage with a significant degree of accuracy in distinguishing between subtypes of non‐small cell lung cancer. Moreover, numerous biomarkers, including RNA molecules, circulating tumor cells, CTCs, and methylated DNA, have been studied in the literature. Many of these biomarkers have a specific high sensitivity and specificity, making them potential candidates for future early detection approaches. Conclusion LDCT is still the golden standard and the only recommended screening procedure for its high sensitivity and specificity and proven cost‐effectiveness. Nevertheless, the notable false positive results acquired during the LDCT examination caused a presumed concern, which drives researchers to investigate better screening procedures and approaches, particularly with the rise of the AI era or by combining two methods in a well‐studied screening program like LDCT and liquid biopsy. we suggest conducting more clinical studies on larger populations with a clear demographical target and adopting approaches for combining one of these new methods with LDCT to decrease false‐positive cases in early detection.

Emerging Non-Invasive Detection Methodologies For Lung Cancer

Emerging Non‑invasive Detection Methodologies for Lung Cancer (Review)

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Optimization of Volatile Markers of Lung Cancer to Exclude Interferences of Non-Malignant Disease

Biomarkers in Early Diagnosis and Screening of Lung Cancer

Biomarkers for Early Diagnosis, Prognosis, Prediction, and Recurrence Monitoring of Non-Small Cell Lung Cancer

Blood-based Tumor Markers in Lung Cancer

[Minimally Invasive Therapies for Early Stage Non-small Cell Lung Cancer].

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Emerging Strategies in Lung Cancer Screening: Blood and Beyond

Molecular Markers and Pathogenically Targeted Therapy in Non-Small Cell Lung Cancer

Nanomedicines Guided Nanoimaging Probes and Nanotherapeutics for Early Detection of Lung Cancer and Abolishing Pulmonary Metastasis: Critical Appraisal of Newer Developments and Challenges to Clinical Transition.

Current and Future Molecular Diagnostics in Non-Small-cell Lung Cancer

Development of new techniques and clinical applications of liquid biopsy in lung cancer management

Emerging electrochemical biosensors for lung cancer-associated protein biomarker and miRNA detection

Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: Critical appraisal of newer developments and challenges to clinical transition

Advances in early detection of non‐small cell lung cancer: A comprehensive review

Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell Lung Cancer.

LC-MS/MS Based Volatile Organic Compound Biomarkers Analysis for Early Detection of Lung Cancer

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Non-Invasive Biomarkers for Early Detection of Breast Cancer